000119621 001__ 119621
000119621 005__ 20240228134945.0
000119621 0247_ $$2doi$$a10.1016/j.neuroscience.2013.07.030
000119621 0247_ $$2pmid$$apmid:23876321
000119621 0247_ $$2ISSN$$a0306-4522
000119621 0247_ $$2ISSN$$a1873-7544
000119621 0247_ $$2altmetric$$aaltmetric:35272460
000119621 037__ $$aDKFZ-2017-00252
000119621 041__ $$aeng
000119621 082__ $$a610
000119621 1001_ $$0P:(DE-He78)adcf3efc31d93c73cbcfa044513c2a93$$aBatora, Nadja$$b0$$eFirst author$$udkfz
000119621 245__ $$aTransitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics.
000119621 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2014
000119621 3367_ $$2DRIVER$$aarticle
000119621 3367_ $$2DataCite$$aOutput Types/Journal article
000119621 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1488448287_15768$$xReview Article
000119621 3367_ $$2BibTeX$$aARTICLE
000119621 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119621 3367_ $$00$$2EndNote$$aJournal Article
000119621 520__ $$aRecent advances in genomic technologies have allowed for tremendous progress in our understanding of the biology underlying medulloblastoma, a malignant childhood brain tumor. Consensus molecular subgroups have been put forth by the pediatric neuro-oncology community and next-generation genomic studies have led to an improved description of driver genes and pathways somatically altered in these subgroups. In contrast to the impressive pace at which advances have been made at the level of the medulloblastoma genome, comparable studies of the epigenome have lagged behind. Complementary data yielded from genomic sequencing and copy number profiling have verified frequent targeting of chromatin modifiers in medulloblastoma, highly suggestive of prominent epigenetic deregulation in the disease. Past studies of DNA methylation-dependent gene silencing and microRNA expression analyses further support the concept of medulloblastoma as an epigenetic disease. In this Review, we aim to summarize the key findings of past reports pertaining to medulloblastoma epigenetics as well as recent and ongoing genomic efforts linking somatic alterations of the genome with inferred deregulation of the epigenome. In addition, we predict what is on the horizon for medulloblastoma epigenetics and how aberrant changes in the medulloblastoma epigenome might serve as an attractive target for future therapies.
000119621 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000119621 588__ $$aDataset connected to CrossRef, PubMed,
000119621 7001_ $$0P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aSturm, Dominik$$b1$$udkfz
000119621 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b2$$udkfz
000119621 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b3$$udkfz
000119621 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b4$$udkfz
000119621 7001_ $$0P:(DE-HGF)0$$aNorthcott, P. A.$$b5$$eLast author
000119621 773__ $$0PERI:(DE-600)1498423-4$$a10.1016/j.neuroscience.2013.07.030$$gVol. 264, p. 171 - 185$$p171 - 185$$tNeuroscience$$v264$$x0306-4522$$y2014
000119621 909CO $$ooai:inrepo02.dkfz.de:119621$$pVDB
000119621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)adcf3efc31d93c73cbcfa044513c2a93$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119621 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000119621 9141_ $$y2014
000119621 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000119621 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119621 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119621 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROSCIENCE : 2015
000119621 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119621 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119621 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119621 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119621 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119621 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119621 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119621 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119621 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119621 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000119621 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000119621 980__ $$ajournal
000119621 980__ $$aVDB
000119621 980__ $$aI:(DE-He78)B062-20160331
000119621 980__ $$aUNRESTRICTED